Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04369560 · ClinicalTrials.gov registry record · Early Phase 1
Virtual Histology of the Bladder Wall for Bladder Cancer Staging
A Early Phase 1 study of Urinary Bladder Neoplasms, sponsored by Jodi Maranchie.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT04369560 is a Early Phase 1 study of Urinary Bladder Neoplasms that is actively recruiting participants, run by Jodi Maranchie. The registered enrollment target is 42 participants, below the 311-participant average among 19 other Urinary Bladder Neoplasms trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04369560, a Early Phase 1 study of Urinary Bladder Neoplasms, is actively recruiting participants, sponsored by Jodi Maranchie.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase Ib study of the safety and performance of a novel intravesical contrast-enhanced Magnetic Resonance Imaging protocol for determination of bladder cancer stage prior to transurethral resection of bladder tumor (21 subjects) or prior to radical cystectomy for muscle invasive disease (21 subjects). Subjects will undergo a single MRI study: a pre-contrast, single breath hold image followed by sterile placement of a temporary urethral catheter for instillation of a 50mL solution containing Gadobutrol (4 mM) plus ferumoxytol (5 mM) and then a second, post-contrast image. Images will be reviewed by two dedicated abdominal radiologists, who are blinded to the pathologic staging, for determination of tumor presence and depth of bladder wall penetration.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Magnetic Resonance Imaging
- DRUG Gadobutrol intravesical administration (4mM)
- DRUG Ferumoxytol intravesical administration (5 mM)
Study Locations (1)
Pennsylvania
- UPMC Hillman Cancer Center - Dept of Urology - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2025-05-23 |
| Est. Completion | 2028-12-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04369560
The ClinicalTrials.gov registry entry for NCT04369560 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 311-participant average among 19 other Urinary Bladder Neoplasms trials with a reported enrollment target (86% lower). The listed sponsor is Jodi Maranchie, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urinary Bladder Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT04369560 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04369560 about?
NCT04369560 is a clinical study titled "Virtual Histology of the Bladder Wall for Bladder Cancer Staging". This is a phase Ib study of the safety and performance of a novel intravesical contrast-enhanced Magnetic Resonance Imaging protocol for determination of bladder cancer stage prior to transurethral resection of bladder tumor (21 subjects) or prior to radical cystectomy for muscle invasive disease (2...
What is the current status of trial NCT04369560?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 42 participants. The study started on 2025-05-23. Estimated completion is 2028-12-30.
What conditions does trial NCT04369560 study?
This clinical trial studies the following conditions: Urinary Bladder Neoplasms.
What interventions are being tested in trial NCT04369560?
The interventions under investigation include: Magnetic Resonance Imaging (DIAGNOSTIC_TEST), Gadobutrol intravesical administration (4mM) (DRUG), Ferumoxytol intravesical administration (5 mM) (DRUG).
Who is sponsoring clinical trial NCT04369560?
This trial is sponsored by Jodi Maranchie, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04369560 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Bladder Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
RECRUITING · Phase 1
-
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RECRUITING · Phase 3
-
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
RECRUITING · Phase 2
-
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.